Skip to main content

Advertisement

Table 1 Characteristics of included studies

From: The effects of alpha-lipoic acid supplementation on inflammatory markers among patients with metabolic syndrome and related disorders: a systematic review and meta-analysis of randomized controlled trials

Authors (Ref) Publication year Sample size (control/intervention) Country/population Intervention (name and daily dose) Duration Presented data Age (y) (control, intervention) Results
Hong et al. [22] 2017 32/30 China/patients with diabetic nephropathy 450 mg ALA (IV) + 20 μg alprostadil 2 weeks CRP, IL-6, TNF-α 65.82 ± 11.63, 67.24 ± 10.81 Decreased CRP, IL-6 and TNF-α
Sardu et al. [25] 2017 40/33 Italy/overweight patients with atrial fibrilation 600 mg ALA 12 months CRP, IL-6, TNF-α 61.5 ± 8.1, 58.8 ± 6.7 Decreased CRP, IL-6 and TNF-α
Huerta et al. [30] 2016 21/19 Spain/overweight and obese women 300 mg ALA 10 weeks CRP, IL-6 range: 20–50 Decreased CRP and IL-6
Huerta et al. [30] 2016 21/17 Spain/overweight and obese women 300 mg ALA + 1.3 g EPA 10 weeks CRP, IL-6 range: 20–50 Decreased CRP
Marfella et al. [28] 2015 21/22 Italy/overweight patients with cardiomyopathy 600 mg ALA 12 months CRP, TNF-α 63.9 ± 5.2, 63.7 ± 6.5 Decreased CRP and TNF-α
Safa et al. [37] 2014 31/30 Iran/patients with ESRD on hemodialysis 600 mg ALA 8 weeks TNF-α 55.20 ± 13.43, 59.3 ± 10.47 No effect
Ahmadi et al. [23] 2013 24/20 Iran/hemodialysis patients 600 mg ALA 2 months CRP, IL-6 48.9 ± 12.5, 48.8 ± 11.2 Decreased CRP and IL-6
Ahmadi et al. [23] 2013 24/24 Iran/hemodialysis patients 600 mg ALA + 400 IU vitamin E 2 months CRP, IL-6 48.9 ± 12.5, 53.2 ± 9.8 Decreased CRP and IL-6
El-Nakib et al. [35] 2013 22/22 Egypt/patients with CRF on hemodialysis 600 mg ALA 3 months IL-6 46.2 ± 14.4, 49.1 ± 16.2 No effect
Hegazy et al. [36] 2013 15/15 Egypt/patients with T1DM 600 mg ALA + insulin 4 months TNF-α 11.1 ± 2.3, 11.9 ± 1.4 Decreased TNF-α
Cinteza al. [32] 2013 14/14 Romania/post acute stroke patients 600 mg ALA + other nutrients 2 weeks IL-6, TNF-α 67.1 ± 10.85, 64 ± 10.85 Decreased IL-6 and TNF-α
Nasole et al. [33] 2013 6/10 Italy/patients with chronic leg wound and metabolic disease 600 mg ALA 2 weeks IL-6, TNF-α 72,59 Decreased IL-6 and TNF-α
Nasole et al. [33] 2013 6/10 Italy/patients with chronic leg wound and metabolic disease 600 mg R-(+)-lipoic acid (RLA) 2 weeks IL-6, TNF-α 72,72 Decreased IL-6 and TNF-α
Khabbazi et al. [27] 2012 28/24 Iran/patients with ESRD on hemodialysis 600 mg ALA 8 weeks CRP 54.04 ± 13.96, 53.83 ± 13.29 Decreased CRP
Manning et al. [24] 2012 39/34 New Zealand/patients with MetS 600 mg ALA 12 months CRP, IL-6, TNF-α 57 ± 9, 55 ± 10 No effect
Zhang et al. [16] 2011 9/13 China/obese patients with impaired glucose tolerance 600 mg ALA (IV) 2 weeks IL-6, TNF-α 52.6 ± 6.2, 52.5 ± 8.2 Decreased IL-6 and TNF-α
Xiang et al. [21] 2011 30/30 China/patients with impaired fasting glucose 600 mg ALA (IV) 3 weeks CRP 58 ± 9, 58 ± 10 Decreased CRP
Gianturco et al. [29] 2009 7/7 Italy/patients with NIDDM 400 mg ALA 4 weeks CRP 58 ± 16, 61 ± 7 No effect
Chang et al. [26] 2007 25/25 Korea/diabetic ESRD patients on hemodialysis 600 mg ALA 12 weeks CRP 66 ± 7, 63 ± 6 No effect
Sola et al. [34] 2005 14/15 USA/patients with MetS 300 mg ALA 4 weeks IL-6 44 ± 13, 46 ± 15 Decreased IL-6
Sola et al. [34] 2005 14/15 USA/patients with MetS 300 mg ALA + 150 mg irbesartan 4 weeks IL-6 44 ± 13, 48 ± 12 Decreased IL-6
Romos et al. [31] 2012 28/30 USA/patients with CKD 600 mg ALA + 666 IU tocopherols 8 weeks CRP, IL-6 64.5 ± 8.8, 58.6 ± 12.0 Decreased IL-6
  1. ALA alpha-lipoic acid, CRF chronic renal failure, CKD chronic kidney disease, ESRD end-stage renal disease, IV intravascular, IL-6 interlokin-6, CRP C-reactive protein, MetS metabolic syndrome, NIDDM non-insulin-dependent diabetes mellitus, TNF-α tumor necrosis factor alpha, T1DM type 1 diabetes mellitus, T2DM type 2 diabetes mellitus